Case seriesPublished 15 Nov 2020
177Lu-PSMA Therapy an Alternative Therapy for Metastatic Castrate Resistant Prostate Cancer with Suboptimal Response: Are we ready for it
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Lutetium-177-PSMA-617 (177Lu-PSMA) is used as the last treatment option in metastatic castrate resistant prostate cancer (mCRPC). We present two cases of mCRPC with bone involvement to see the response of 177Lu-PSMA as an alternative treatment option. Case presentations: We present two cases, diagnosed as mCRPC with bone involvement, having suboptimal labelling and binding of the tracer and its effect on bone marrow. The two patients had 2-4 cycles of 177Lu-PSMA with progressive disease despite chemotherapy and novel androgen therapy. The response of treatment was determined based on changes in radiological findings, biochemical and post-therapeutic scan. The last post therapy SPECT CT 99mTc-PSMA scans in both patients showed diffuse homogenous tracer distribution in the bone marrow with no suggestion of receptor avid disease. In both patients the PSA level decreased. Side effects seen were pancytopenia and mild increase in creatinine and urea. Conclusion: The main benefit of 177Lu-PSMA is to offer an alternative therapeutic option for patient with disease progression despite first line of treatment. We advocate a repeat scan is required after every treatment session with 177Lu-PSMA to ensure adequate radioisotope uptake and to assess for therapeutic response. A patient specific dosimetric approach should be applied before therapy to prevent organ toxicity.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEuropean Journal of Clinical Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Sharifa Al Sheebani”
- BylineArticles whose byline prints “Ajda Altinoz”
- BylineArticles whose byline prints “Lutfi A Kurban”
- BylineArticles whose byline prints “Saadia Ibrahim”
- BylineArticles whose byline prints “Gehad Nassar”
- BylineArticles whose byline prints “Hussam Sadaqa”
- BylineArticles whose byline prints “Jawaher A Ansari”
- BylineArticles whose byline prints “Sulaman R Magdub”
